GRPR and neoplasm: Prior work of our group on 177Lu-labeled GRPR antagonists with modifications at the Gln7-Trp8 site within the pharmacophore [29] in the biological behavior of bombesin derivatives revealed that the introduction of homoserine (Hse7) and β-(3-benzothienyl) alanine (Bta8) into the MJ9 (H-Pip5-phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) peptide might result in increased tumor-to-abdomen ratios.